|
Polycythemia Vera
|
0.040 |
PosttranslationalModification
|
disease |
BEFREE |
In the present work, we investigated the mechanism responsible for Lu/BCAM phosphorylation in the presence of JAK2V617F using HEL and BaF3 cell lines as well as RBCs from patients with PV.
|
23160466 |
2013 |
|
Polycythemia Vera
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
CD239 was expressed in a constitutive fashion in PV-derived bone marrow cells and thus a pro-thrombotic function does not seem to be mediated by increased CD239 expression alone.
|
18972067 |
2009 |
|
Polycythemia Vera
|
0.040 |
Biomarker
|
disease |
BEFREE |
This observation suggests that Lu/BCAM could participate to the high incidence of vascular thrombosis that also characterizes PV disease.
|
18948049 |
2008 |
|
Polycythemia Vera
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our results indicate that JAK2 mutation might be linked to Lu/BCAM modification and increased RBC adhesiveness, which may be a factor favoring thrombosis in PV.
|
17412890 |
2007 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
It also is necessary to investigate further the interaction between Lu/B-CAM and laminin a5 in pathological processes, including sickle cell disease and cancer.
|
16546822 |
2005 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
A unique gene encodes spliceoforms of the B-cell adhesion molecule cell surface glycoprotein of epithelial cancer and of the Lutheran blood group glycoprotein.
|
8781446 |
1996 |
|
Myeloproliferative disease
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Erythrocytes from patients with myeloproliferative neoplasms and splanchnic venous thrombosis show greater expression of Lu/BCAM.
|
29756283 |
2018 |
|
Myeloproliferative disease
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Furthermore, our study shows deregulation of Lu/BCAM and CD147 that are two ubiquitously expressed proteins linked to progression of solid tumors, paving the way for future studies to address the role of hydroxycarbamide in tissues other than blood cells in myeloproliferative neoplasms.
|
29599206 |
2018 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
This study was performed to investigate the role and downstream signaling pathway of Lu/BCAM in human bladder tumorigenesis.
|
28841878 |
2017 |
|
Liver carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical studies showed that although the expression of Lu/B-CAM was observed in most HCCs, MT1-MMP was not always expressed in tumor tissues, suggesting that a part of Lu/B-CAM in plasma of HCC patients was also released in a MMP-independent manner.
|
25051049 |
2014 |
|
Neoplasm Metastasis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Thus, these data indicate that BCAM is a suppressive oncoprotein, and that FBI1/Akirin2 is involved in tumorigenicity and metastasis of hepatoma through the downregulation of suppressive oncogenes.
|
24223164 |
2013 |
|
Neoplasm Metastasis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
We, also, found a correlation between decreased BCAM expression and tumor size or presence of metastasis.
|
23168236 |
2013 |
|
Neoplasm Metastasis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
We conclude that tumor cell migration on LM-511 requires that Lu/B-CAM competitively modulates cell attachment through integrins.
|
24036115 |
2013 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
However, the function of BCAM in carcinogenesis is poorly understood.
|
24223164 |
2013 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Another carcinogenesis-associated antigen is Lutheran or BCAM (basal cell adhesion molecule), a surface glycoprotein that acts as a receptor for the extracellular matrix protein, laminin.
|
23168236 |
2013 |
|
Liver carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Thus, these data indicate that BCAM is a suppressive oncoprotein, and that FBI1/Akirin2 is involved in tumorigenicity and metastasis of hepatoma through the downregulation of suppressive oncogenes.
|
24223164 |
2013 |
|
Myeloproliferative disease
|
0.030 |
GeneticVariation
|
group |
BEFREE |
More recently, we demonstrated that constitutive phosphorylation of Lu/BCAM is also involved in abnormal RBC adhesion to endothelium in patients with polycythemia vera (PV), a frequent myeloproliferative disorders associated with the V617F mutation of the tyrosine kinase JAK2 leading to continuous stimulation of erythropoiesis.
|
18948049 |
2008 |
|
Liver carcinoma
|
0.030 |
Biomarker
|
disease |
LHGDN |
Laminin alpha 5 mediates ectopic adhesion of hepatocellular carcinoma through integrins and/or Lutheran/basal cell adhesion molecule.
|
18635166 |
2008 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our results show that CD239 is a promising antigen for ADC-based breast cancer therapy.
|
29700410 |
2018 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
The non-BCAM (Breast cancer awareness month) group were screened from February to September 2016 and the BCAM group during October 2016.
|
28351284 |
2018 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The non-BCAM (Breast cancer awareness month) group were screened from February to September 2016 and the BCAM group during October 2016.
|
28351284 |
2018 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our results show that CD239 is a promising antigen for ADC-based breast cancer therapy.
|
29700410 |
2018 |
|
Tumor Progression
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
These results suggest that soluble Lu/B-CAM serves as not only a novel marker for HCC but also a modulator in tumor progression.
|
25051049 |
2014 |
|
Tumor Progression
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
BCAM is a protein related to tumor progression; and, its over expression is associated with skin, ovarian and pancreatic cancers.
|
23168236 |
2013 |
|
Influenza
|
0.010 |
Biomarker
|
disease |
BEFREE |
We detected specific IgG against influenza B virus in 83% of the children diagnosed with BCAM.
|
28795360 |
2018 |